• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

Cuba encouraged by early trials of homegrown COVID-19 vaccine

firstwordpharmaJune 21, 2021

Tag: Cuba , COVID-19 , Vaccine

Cuba's state-run biopharmaceutical corporation BioCubaFarma said preliminary data from late phase trials showed that the Soberana 2 vaccine candidate for COVID-19 had 62% efficacy with just two of its three doses, as reported Fidelity.

Cuba encouraged by early trials of homegrown COVID-19 vaccine

"In a few weeks we should have the results for the efficacy with three doses which we expect will be superior," said Vicente Vérez, director of the Finlay Vaccine Institute, which developed Soberana 2.

Several countries from have expressed an interest in buying Cuba's vaccines, and Iran started producing Soberana 2 earlier this year as part of late-phase trials.

Previous:Israeli scientists find promising target for breast cancer and other cancer therapeutics

Next:China's Sinopharm COVID-19 vaccines arrive in Thailand

Related News

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

PeproMene Bio, Inc.has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory (r/r) follicular lymphoma.

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

You may like
More>>

Biochemistry Incubator

Biochemistry Incubator
Incubator With Illumination SPX-GBH

Incubator With Illumination SPX-GBH
Rabies Vaccine(Human Diploid Cell)

Rabies Vaccine(Human Diploid Cell)
vaccine bioreactor system

vaccine bioreactor system
Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine
Incubator Shaker HPY-91

Incubator Shaker HPY-91
B11 100ml amber plastic vaccine bottle

B11 100ml amber plastic vaccine bottle
Hangzhou economic development zone no. 6 street 5 b03 high-tech incubator building 1, 452

Hangzhou economic development zone no. 6 street 5 b03 high-tech incubator building 1, 452
DTaP-Hib combined Vaccine

DTaP-Hib combined Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service